Seres Therapeutics, Inc. Investment Income, Interest
Seres Therapeutics, Inc. (MCRB) reported Investment Income, Interest of $181.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Seres Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $181.00K, a 66.85% decline year-over-year.
- Seres Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $325.00K, a 47.41% decline year-over-year.
- Seres Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $445.00K, a 1.83% increase year-over-year.
- Seres Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $618.00K, a 5.21% decline year-over-year.
- Seres Therapeutics, Inc. investment income, interest for fiscal 2025 was $2.23M, a 43.86% decline from fiscal 2024.
- Seres Therapeutics, Inc. investment income, interest for fiscal 2024 was $3.97M, a 45.66% decline from fiscal 2023.
- Seres Therapeutics, Inc. investment income, interest for fiscal 2023 was $7.30M, a 138.75% increase from fiscal 2022.
- Seres Therapeutics, Inc. investment income, interest for fiscal 2022 was $3.06M, a 6.55% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $181.00K 10-Q · filed 2026-08-05 | $506.00K 10-Q · filed 2026-08-05 | $951.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $325.00K 10-Q · filed 2026-05-05 | $770.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.39M derived: sum of 3 quarters · filed 2026-05-05 | $1.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.06M derived: sum of 2 quarters · filed 2026-03-12 | $1.61M derived: sum of 3 quarters · filed 2026-08-05 | $2.23M 10-K · filed 2026-03-12 |
| 2025-09-30 | $618.00K 10-Q · filed 2025-11-05 | $1.16M derived: sum of 2 quarters · filed 2026-08-05 | $1.78M 10-Q · filed 2025-11-05 | $2.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $546.00K 10-Q · filed 2026-08-05 | $1.16M 10-Q · filed 2026-08-05 | $1.60M derived: sum of 3 quarters · filed 2026-08-05 | $2.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $618.00K 10-Q · filed 2026-05-05 | $1.05M derived: sum of 2 quarters · filed 2026-05-05 | $1.71M derived: sum of 3 quarters · filed 2026-05-05 | $2.94M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.09M derived: sum of 2 quarters · filed 2026-03-12 | $2.32M derived: sum of 3 quarters · filed 2026-03-12 | $3.97M 10-K · filed 2026-03-12 |
| 2024-09-30 | $652.00K 10-Q · filed 2025-11-05 | $1.88M derived: sum of 2 quarters · filed 2025-11-05 | $3.53M 10-Q · filed 2025-11-05 | $5.50M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $1.23M 10-Q · filed 2025-08-06 | $2.88M 10-Q · filed 2025-08-06 | $4.85M derived: sum of 3 quarters · filed 2026-03-12 | $7.42M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $1.65M 10-Q · filed 2025-05-07 | $3.62M derived: sum of 2 quarters · filed 2026-03-12 | $6.19M derived: sum of 3 quarters · filed 2026-03-12 | $7.92M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.54M derived: sum of 2 quarters · filed 2026-03-12 | $6.27M derived: sum of 3 quarters · filed 2026-03-12 | $7.30M 10-K · filed 2026-03-12 |
| 2023-09-30 | $2.57M 10-Q · filed 2024-11-13 | $4.30M derived: sum of 2 quarters · filed 2024-11-13 | $5.33M 10-Q · filed 2024-11-13 | $6.74M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $1.73M 10-Q · filed 2024-08-13 | $2.76M 10-Q · filed 2024-08-13 | $4.17M derived: sum of 3 quarters · filed 2025-03-13 | $5.04M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-08 | $2.45M derived: sum of 2 quarters · filed 2025-03-13 | $3.31M derived: sum of 3 quarters · filed 2025-03-13 | $3.71M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.28M derived: sum of 2 quarters · filed 2025-03-13 | $2.67M derived: sum of 3 quarters · filed 2025-03-13 | $3.06M 10-K · filed 2025-03-13 |
| 2022-09-30 | $865.00K 10-Q · filed 2023-11-02 | $1.26M derived: sum of 2 quarters · filed 2023-11-02 | $1.64M 10-Q · filed 2023-11-02 | $2.13M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $395.00K 10-Q · filed 2023-08-08 | $779.00K 10-Q · filed 2023-08-08 | $1.26M derived: sum of 3 quarters · filed 2024-03-05 | $1.85M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $384.00K 10-Q · filed 2023-05-09 | $869.00K derived: sum of 2 quarters · filed 2024-03-05 | $1.46M derived: sum of 3 quarters · filed 2024-03-05 | $2.29M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.07M derived: sum of 2 quarters · filed 2024-03-05 | $1.90M derived: sum of 3 quarters · filed 2024-03-05 | $2.87M 10-K · filed 2024-03-05 |
| 2021-09-30 | $590.00K 10-Q · filed 2022-11-02 | $1.42M derived: sum of 2 quarters · filed 2022-11-02 | $2.38M 10-Q · filed 2022-11-02 | $3.00M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $829.00K 10-Q · filed 2022-08-03 | $1.79M 10-Q · filed 2022-08-03 | $2.41M derived: sum of 3 quarters · filed 2023-03-07 | $2.51M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $966.00K 10-Q · filed 2022-05-04 | $1.58M derived: sum of 2 quarters · filed 2023-03-07 | $1.68M derived: sum of 3 quarters · filed 2023-03-07 | $1.75M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $613.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $713.00K derived: sum of 2 quarters · filed 2023-03-07 | $787.00K derived: sum of 3 quarters · filed 2023-03-07 | $946.00K 10-K · filed 2023-03-07 |
| 2020-09-30 | $100.00K 10-Q · filed 2021-11-10 | $174.00K derived: sum of 2 quarters · filed 2021-11-10 | $333.00K 10-Q · filed 2021-11-10 | $622.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $74.00K 10-Q · filed 2021-08-03 | $233.00K 10-Q · filed 2021-08-03 | $522.00K derived: sum of 3 quarters · filed 2022-03-01 | $857.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $159.00K 10-Q · filed 2021-05-04 | $448.00K derived: sum of 2 quarters · filed 2022-03-01 | $783.00K derived: sum of 3 quarters · filed 2022-03-01 | $972.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $624.00K derived: sum of 2 quarters · filed 2022-03-01 | $813.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.03M 10-K · filed 2022-03-01 |
| 2019-09-30 | $335.00K 10-Q · filed 2020-11-09 | $524.00K derived: sum of 2 quarters · filed 2020-11-09 | $744.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $189.00K 10-Q · filed 2020-07-28 | $409.00K 10-Q · filed 2020-07-28 | ||
| 2019-03-31 | $220.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $1.17M 10-K · filed 2021-03-02 | |||
| 2017-12-31 | $1.59M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |